NATAP REPORTS
National AIDS Treatment Advocacy Project

SPRING 2001

8th Annual Retrovirus Conference

Publisher Jules Levin Edited by Harvey S. Bartnof, MD & Jules Levin Design & Production by Chris Real


Introduction

Treatment Strategies including Treatment Interruptions
and Starting Therapy During Acute Infection

When to Start (& change) Treatment

Viral Rebound: viral load blips & low-level rebound
Intensification, More Potent HAART may prevent failure

New Experimental HIV Drugs
new amprenavir pro-drug, PMPA, T-20, FTC, IL-2, and others

Clinical Studies
Updated DHHS Treatmemt Guidelines, When to Begin Therapy Studies, Kaletra, NNRTIs, 2-Year efavirenz Follow-up, d4T, new EC ddI, Once Daily Regimen Studies 3TC, FTC, Amprenavir, indinavir, Trizivir

Adverse Effects & Complications
Lipodystrophy (Fat Redistribution), Metabolic Complications, Pancreatitis, Bone Disorders, Hepatotoxicity

Hepatitis-HIV Coinfection
Liver transplants, false negatives, incidence in MSM,Hepatitis A, Response to HCV Therapy, lipodystrophy in coinfection, Adefovir for Hepatitis B

Drug-Drug Interactions & Pharmacology
Virtual IQ,Garlic, Pot

Worrisome Trends in Transmission of Drug Resistant Virus

Drug Resistance Testing
Kaletra, abacavir cut-offs, resistance testing

Opportunistic Infections & Neurologic Conditions
Neuropathy, cancers

Women's Issues
Complications, peri-natal transmission

Transmission & Population Studies (Epidemiology)
High Rates of HIV in African-American & Hispanic Men who have Sex With Men; HIV during Acute Infection may be most contagious; CDC SAFE Program to increase testing & access to health care

Adherence to Dosing of Anti-HIV Treatments

WRITTEN BY:

Judith Aberg, MD
Washington University School of Medicine in St. Louis, Missouri

Harvey S. Bartnof, MD
Staff Physician at AVERI (AIDS Virus Education  and Research Institute in San Francisco, CA)

Gilbert Kaufman, MD
University Hospital Basel, Switzerland

Jules Levin
Executive Director of NATAP in New York City, New York

David Margolis, MD
University of Texas Southwestern Medical Center

Graeme Moyle, MD, MBBS
Chelsea and Westminster Hospital in London, UK

Christopher D. Pilcher, MD
University of North Carolina at Chapel Hill

Stephen C. Piscitelli, PharmD
at Virco, formerly with the US NIH

Nancy Shulman, MD
Stanford University School of Medicine, Palo Alto, CA

Kathleen Squires, MD
University of Southern California, LA, CA

David Alain Wohl, MD
University of North Carolina at Chapel Hill

Andrew Zolopa, MD
Stanford University School of Medicine, Palo Alto, CA

The information in this newsletter is only for educational purposes. Before making any treatment decisions, one should consult with one’s doctor(s).

< All newsletters
NATAP home >